Testing effectiveness (Phase 2)Ended earlyNCT03690869
What this trial is testing
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Who this might be right for
Relapsed Solid TumorRefractory Solid TumorRelapsed Central Nervous System Tumor+3 more
Regeneron Pharmaceuticals 57